Axon Enterprise, Inc (NASDAQ:AXON) Given Average Recommendation of “Moderate Buy” by Analysts

Axon Enterprise, Inc (NASDAQ:AXON) has earned a consensus recommendation of “Moderate Buy” from the seventeen analysts that are presently covering the company, MarketBeat Ratings reports. Three research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $805.7143.

A number of brokerages have recently commented on AXON. Piper Sandler reduced their target price on shares of Axon Enterprise from $893.00 to $753.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Northcoast Research raised Axon Enterprise from a “neutral” rating to a “buy” rating and set a $742.00 price objective on the stock in a research note on Tuesday, January 6th. The Goldman Sachs Group reduced their price objective on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Barclays decreased their target price on Axon Enterprise from $861.00 to $702.00 and set an “overweight” rating for the company in a research report on Thursday, November 6th. Finally, Cowen reissued a “buy” rating on shares of Axon Enterprise in a research report on Wednesday, November 5th.

Axon Enterprise Stock Down 1.9%

NASDAQ:AXON opened at $629.22 on Friday. Axon Enterprise has a twelve month low of $469.24 and a twelve month high of $885.91. The company has a market cap of $49.65 billion, a price-to-earnings ratio of 199.12, a price-to-earnings-growth ratio of 20.20 and a beta of 1.41. The stock has a fifty day simple moving average of $569.51 and a 200-day simple moving average of $684.53. The company has a current ratio of 3.12, a quick ratio of 2.89 and a debt-to-equity ratio of 0.57.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The company had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.The company’s revenue for the quarter was up 30.6% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.45 earnings per share. Analysts anticipate that Axon Enterprise will post 5.8 EPS for the current year.

Insider Buying and Selling

In other news, CFO Brittany Bagley sold 2,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The shares were sold at an average price of $580.00, for a total value of $1,160,000.00. Following the completion of the sale, the chief financial officer owned 103,501 shares of the company’s stock, valued at approximately $60,030,580. This represents a 1.90% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Patrick W. Smith sold 10,000 shares of the stock in a transaction that occurred on Wednesday, January 7th. The shares were sold at an average price of $619.01, for a total transaction of $6,190,100.00. Following the transaction, the chief executive officer owned 3,100,997 shares in the company, valued at approximately $1,919,548,152.97. This represents a 0.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 60,540 shares of company stock valued at $34,684,738 over the last quarter. 4.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On Axon Enterprise

Large investors have recently bought and sold shares of the business. Vestor Capital LLC boosted its position in Axon Enterprise by 438,636.3% during the 2nd quarter. Vestor Capital LLC now owns 833,599 shares of the biotechnology company’s stock valued at $690,170,000 after acquiring an additional 833,409 shares in the last quarter. Norges Bank purchased a new stake in shares of Axon Enterprise during the 2nd quarter worth $637,806,000. Vanguard Group Inc. lifted its stake in shares of Axon Enterprise by 4.2% during the 3rd quarter. Vanguard Group Inc. now owns 9,314,164 shares of the biotechnology company’s stock worth $6,684,217,000 after purchasing an additional 376,904 shares during the last quarter. Jennison Associates LLC boosted its position in Axon Enterprise by 53.8% during the third quarter. Jennison Associates LLC now owns 943,944 shares of the biotechnology company’s stock valued at $677,412,000 after purchasing an additional 330,213 shares in the last quarter. Finally, McElhenny Sheffield Capital Management LLC bought a new stake in Axon Enterprise during the second quarter valued at about $255,833,000. Institutional investors own 79.08% of the company’s stock.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.